CENTANNI, Stefano
 Distribuzione geografica
Continente #
AS - Asia 135
NA - Nord America 86
EU - Europa 42
SA - Sud America 33
AF - Africa 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 299
Nazione #
US - Stati Uniti d'America 80
SG - Singapore 65
IT - Italia 28
BR - Brasile 27
CN - Cina 25
VN - Vietnam 22
IN - India 13
GB - Regno Unito 6
MX - Messico 4
DE - Germania 3
HK - Hong Kong 3
AR - Argentina 2
BD - Bangladesh 2
CA - Canada 2
LT - Lituania 2
MA - Marocco 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
EC - Ecuador 1
FI - Finlandia 1
IQ - Iraq 1
JP - Giappone 1
NL - Olanda 1
PK - Pakistan 1
PL - Polonia 1
VE - Venezuela 1
Totale 299
Città #
Singapore 28
Bengaluru 13
Hefei 13
Ho Chi Minh City 11
Santa Clara 11
Milan 8
Dallas 7
Ashburn 6
Hanoi 5
Naples 4
New York 4
Beijing 3
Chicago 3
Hong Kong 3
Lawrence 3
Muggiò 3
Munich 3
Princeton 3
Rome 3
San Francisco 3
Assago 2
Atlanta 2
Brooklyn 2
Campobasso 2
Charlotte 2
Da Nang 2
Des Moines 2
London 2
Maldonado 2
Palermo 2
San Nicola Manfredi 2
São Paulo 2
Anápolis 1
Baku 1
Belo Horizonte 1
Boa Vista 1
Boydton 1
Bắc Ninh 1
Cachoeiro de Itapemirim 1
Caracas 1
Carandaí 1
Cincinnati 1
Contagem 1
Corpus Christi 1
Corrientes 1
Cuauhtémoc 1
Curitiba 1
Dubai 1
Fortaleza 1
Guarulhos 1
Harrisburg 1
Hermoso Campo 1
Itanhém 1
Itapevi 1
Itu 1
Içara 1
Legnago 1
Los Angeles 1
Manaus 1
Mesquite 1
Mexico City 1
Monte Alto 1
Montreal 1
Ninh Bình 1
Norwalk 1
Nova Iguaçu 1
Passo Fundo 1
Philadelphia 1
Phoenix 1
Piraju 1
Portão 1
Preston 1
Quito 1
Rabat 1
Raleigh 1
Reynosa 1
Rhyl 1
Salé 1
Seattle 1
Soledade 1
Sumaré 1
São Gabriel 1
São José 1
São Pedro 1
The Dalles 1
Thái Nguyên 1
Tokyo 1
Três Pontas 1
Turku 1
Warsaw 1
Wilmington 1
Totale 220
Nome #
Profiling severe asthma: Any relevance for age? An analysis from Severe Asthma Network Italy (SANI) cohort 33
Durability of benralizumab effectiveness in severe eosinophilic asthma patients with and without chronic rhinosinusitis with nasal polyps: a post hoc analysis from the ANANKE study 28
Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study 28
Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry 28
Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis 27
Reply to: Kow CS et al. Are severe asthma patients at higher risk of developing severe outcomes from COVID-19? 27
Point-of-Care Lung Sonography: An Audit of 1150 Examinations 25
ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study 24
Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis 22
Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study 19
Lung Ultrasound B Lines: Etiologies and Evolution with Age 18
COVID-19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments 18
Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study 17
Totale 314
Categoria #
all - tutte 3.753
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.753


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20228 0 0 0 0 0 0 2 2 0 1 3 0
2022/202310 6 0 0 1 1 1 0 1 0 0 0 0
2023/202425 5 1 3 0 0 5 1 2 0 3 5 0
2024/202588 16 2 3 1 2 13 14 5 1 2 17 12
2025/2026180 34 32 22 48 44 0 0 0 0 0 0 0
Totale 314